To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question

被引：0
|
作者：
Lukasik, Zuzanna [1 ,2 ]
Carron, Philippe [1 ,2 ]
Webers, Casper [3 ,4 ]
机构：
[1] Univ Ghent, Ghent Univ Hosp, Dept Internal Med & Pediat, Ghent, Belgium
[2] VIB Ctr Inflammat Res, Ghent, Belgium
[3] Maastricht Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Maastricht, Netherlands
[4] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands
来源：
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2023年 / 37卷 / 03期
关键词：
Axial spondyloarthritis; Tapering; Discontinuation; Remission; Therapy; Biological DMARD; SOCIETY CLASSIFICATION CRITERIA; ASAS-EULAR RECOMMENDATIONS; ANKYLOSING-SPONDYLITIS; PSORIATIC-ARTHRITIS; DOSE REDUCTION; PERIPHERAL SPONDYLOARTHRITIS; RHEUMATOID-ARTHRITIS; NON-INFERIORITY; TNF-INHIBITORS; DOUBLE-BLIND;
D O I：
10.1016/j.berh.2023.101869
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页数：17
相关论文
共 50 条
  • [31] THE EFFECT OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (bDMARDs) IN TARGETING DISEASE REMISSION IN AXIAL SPONDYLOARTHRITIS (axSpA): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Cruz-Machado, A. R.
    Manica, S. R.
    Silva, J. L.
    Pimentel-Santos, F. M.
    Tavares-Costa, J.
    Vieira-Sousa, E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 731 - 731
  • [32] Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies
    Caso, Francesco
    Costa, Luisa
    Del Puente, Antonio
    Di Minno, Matteo Nicola Dario
    Lupoli, Gelsy
    Scarpa, Raffaele
    Peluso, Rosario
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (06) : 328 - 338
  • [33] The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
    Manica, Santiago Rodrigues
    Silva, Joana Leite
    Machado, Ana Rita
    Coelho, Constanca
    Duarte, Joana
    Vieira-Sousa, Elsa
    Costa, Jose Tavares
    Pimentel-Santos, Fernando
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [34] The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
    Denis, Agathe
    Sztejkowski, Cedric
    Arnaud, Laurent
    Becker, Guillaume
    Felten, Renaud
    RMD OPEN, 2023, 9 (03):
  • [35] The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Otani, Hiroshi
    Abe, Asami
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    INTERNAL MEDICINE, 2023, 62 (03) : 373 - 379
  • [36] Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis
    Ribeiro, Andre Lucas
    Abarza, Virginia Carrizo
    Gladman, Dafna
    Chandran, Vinod
    Eder, Lihi
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4728 - 4730
  • [37] Development of active tuberculosis in patients treated with biological disease-modifying antirheumatic drugs
    Strong, J.
    Mann, T. N.
    Tar, G. S.
    Reuter, H.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2022, 112 (02): : 76 - 80
  • [38] Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis
    Shridharmurthy, Divya
    Lapane, Kate L.
    Baek, Jonggyu
    Nunes, Anthony P.
    Weisman, Michael H.
    Kay, Jonathan
    Liu, Shao-Hsien
    ARTHRITIS CARE & RESEARCH, 2024, 76 (08) : 1149 - 1161
  • [39] Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia
    Hopkins, Ashley M.
    Proudman, Susanna M.
    Vitry, Agnes I.
    Sorich, Michael J.
    Cleland, Leslie G.
    Wiese, Michael D.
    MEDICAL JOURNAL OF AUSTRALIA, 2016, 204 (02) : 64 - +
  • [40] Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain
    Silva-Fernandez, Lucia
    Perez-Vicente, Sabina
    Auxiliadora Martin-Martinez, Maria
    Lopez-Gonzalez, Ruth
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 44 (06) : 633 - 640
12345